These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38272714)

  • 1. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
    Pilotto F; Chellapandi DM; Puccio H
    Trends Mol Med; 2024 Feb; 30(2):117-125. PubMed ID: 38272714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia.
    Bit-Avragim N; Perrot A; Schöls L; Hardt C; Kreuz FR; Zühlke C; Bubel S; Laccone F; Vogel HP; Dietz R; Osterziel KJ
    J Mol Med (Berl); 2001; 78(11):626-32. PubMed ID: 11269509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dynamin-related protein 1 is decreased and the mitochondrial network is altered in Friedreich's ataxia cardiomyopathy.
    Chidipi B; Angulo MB; Shah SI; Rieser M; Ullah G; McDonald TV; Noujaim SF
    Int J Biochem Cell Biol; 2022 Feb; 143():106137. PubMed ID: 34923139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
    Profeta V; McIntyre K; Wells M; Park C; Lynch DR
    Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.
    Igoillo-Esteve M; Oliveira AF; Cosentino C; Fantuzzi F; Demarez C; Toivonen S; Hu A; Chintawar S; Lopes M; Pachera N; Cai Y; Abdulkarim B; Rai M; Marselli L; Marchetti P; Tariq M; Jonas JC; Boscolo M; Pandolfo M; Eizirik DL; Cnop M
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a Friedreich's Ataxia patient-derived iPSC line USFi001-A.
    Angulo MB; Yang J; Argenziano MA; Bertalovitz AC; Beidokhti MN; McDonald TV
    Stem Cell Res; 2021 Jul; 54():102399. PubMed ID: 34034220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omaveloxolone: potential new agent for Friedreich ataxia.
    Lynch DR; Johnson J
    Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiple animal and cellular models approach to study frataxin deficiency in Friedreich Ataxia.
    Mosbach V; Puccio H
    Biochim Biophys Acta Mol Cell Res; 2024 Oct; 1871(7):119809. PubMed ID: 39134123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the ferroptosis pathways in dorsal root ganglia of Friedreich ataxia models. The role of LKB1/AMPK, KEAP1, and GSK3β in the impairment of the NRF2 response.
    Sanz-Alcázar A; Portillo-Carrasquer M; Delaspre F; Pazos-Gil M; Tamarit J; Ros J; Cabiscol E
    Redox Biol; 2024 Oct; 76():103339. PubMed ID: 39243573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data.
    Gunther K; Lynch DR
    Expert Opin Pharmacother; 2024 Apr; 25(5):529-539. PubMed ID: 38622054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omaveloxolone: First Approval.
    Lee A
    Drugs; 2023 Jun; 83(8):725-729. PubMed ID: 37155124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
    Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Overview of the Ferroptosis Hallmarks in Friedreich's Ataxia.
    Turchi R; Faraonio R; Lettieri-Barbato D; Aquilano K
    Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33126466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified mouse model of Friedreich's ataxia with conditional
    Perfitt TL; Huichalaf C; Gooch R; Kuperman A; Ahn Y; Chen X; Ullas S; Hirenallur-Shanthappa D; Zhan Y; Otis D; Whiteley LO; Bulawa C; Martelli A
    Am J Physiol Heart Circ Physiol; 2024 Feb; 326(2):H357-H369. PubMed ID: 38038720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Friedreich's ataxia: past, present and future.
    Marmolino D
    Brain Res Rev; 2011 Jun; 67(1-2):311-30. PubMed ID: 21550666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An In Silico Analysis of Genetic Variants and Structural Modeling of the Human Frataxin Protein in Friedreich's Ataxia.
    Da Conceição LMA; Cabral LM; Pereira GRC; De Mesquita JF
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.
    Alfedi G; Luffarelli R; Condò I; Pedini G; Mannucci L; Massaro DS; Benini M; Toschi N; Alaimo G; Panarello L; Pacini L; Fortuni S; Serio D; Malisan F; Testi R; Rufini A
    Mov Disord; 2019 Mar; 34(3):323-334. PubMed ID: 30624801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress.
    Gomes CM; Santos R
    Oxid Med Cell Longev; 2013; 2013():487534. PubMed ID: 23936609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NRF2 Signaling Network Defines Clinical Biomarkers and Therapeutic Opportunity in Friedreich's Ataxia.
    La Rosa P; Bertini ES; Piemonte F
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroptosis in Friedreich's Ataxia: A Metal-Induced Neurodegenerative Disease.
    La Rosa P; Petrillo S; Fiorenza MT; Bertini ES; Piemonte F
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33202971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.